{"content":"<li class=\"n-box-item date-title\" data-end=\"1576731599\" data-start=\"1576645200\" data-txt=\"Monday, December 23, 2019\">Wednesday, December 18, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3527296\" data-ts=\"1576724261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWST\" target=\"_blank\">TWST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527296-twist-bio-inks-50m-stock-sales-deal-cowen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twist Bio inks $50M stock sales deal with Cowen</a></h4><ul><li>Twist Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/TWST' title='Twist Bioscience Corporation'>TWST</a>) has entered into an <a href=\"https://www.sec.gov/Archives/edgar/data/1581280/000119312519317753/d806151d8k.htm\" target=\"_blank\">agreement </a>with Cowen and Company for the at-the-market sale of up to $50M of its common stock. Cowen will earn a 3% commission for its efforts.</li><li>Shares down <font color=\"red\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527296\" data-linked=\"Twist Bio inks $50M stock sales deal with Cowen\" data-tweet=\"$TWST - Twist Bio inks $50M stock sales deal with Cowen https://seekingalpha.com/news/3527296-twist-bio-inks-50m-stock-sales-deal-cowen?source=tweet\" data-url=\"https://seekingalpha.com/news/3527296-twist-bio-inks-50m-stock-sales-deal-cowen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527295\" data-ts=\"1576724076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527295-epizyme-files-u-s-application-for-tazemetostat-for-follicular-lymphoma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme files U.S. application for tazemetostat for follicular lymphoma</a></h4><ul><li>Fresh off today's <a href=\"https://seekingalpha.com/news/3527217-epizyme-up-12-after-advisory-committee-nod-on-tazemetostat\" target=\"_blank\">positive advisory committee vote</a> backing tazemetostat for epithelioid sarcoma, Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme, Inc.'>EPZM</a>) files another marketing application with the FDA for the EZH2 inhibitor.</li><li>The <a href=\"https://seekingalpha.com/pr/17732454-epizyme-submits-new-drug-application-to-u-s-fda-for-tazemetostat-for-treatment-of-patients\" target=\"_blank\">new indication</a> is relapsed/refractory follicular lymphoma, with or without EZH2 mutations, in patients who have received at least two prior lines of therapy.</li><li>The company is seeking accelerated approval of the filing.</li><li>Shares up <font color=\"green\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527295\" data-linked=\"Epizyme files U.S. application for tazemetostat for follicular lymphoma\" data-tweet=\"$EPZM - Epizyme files U.S. application for tazemetostat for follicular lymphoma https://seekingalpha.com/news/3527295-epizyme-files-u-s-application-for-tazemetostat-for-follicular-lymphoma?source=tweet\" data-url=\"https://seekingalpha.com/news/3527295-epizyme-files-u-s-application-for-tazemetostat-for-follicular-lymphoma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527294\" data-ts=\"1576723561\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGEN\" target=\"_blank\">SGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527294-fda-oks-seattle-genetics-adc-for-urothelial-cancer-shares-up-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Seattle Genetics ADC for urothelial cancer; shares up 6% after hours</a></h4><ul><li>Under accelerated review status, the FDA <a href=\"https://seekingalpha.com/pr/17732524-fda-grants-accelerated-approval-to-astellas-and-seattle-genetics-padcev-enfortumab-vedotin\" target=\"_blank\">approves </a>Seattle Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGEN' title='Seattle Genetics, Inc.'>SGEN</a>) and collaboration partners Astellas Pharma's (<a href='https://seekingalpha.com/symbol/ALPMF' title='Astellas Pharma Inc.'>OTCPK:ALPMF</a>) antibody-drug conjugate &#40;ADC&#41; Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and platinum-containing chemo before (neoadjuvant) or after (adjuvant) surgery.</li><li>SGEN will host a <a href=\"https://seekingalpha.com/pr/17732506-seattle-genetics-to-host-conference-call-and-webcast-on-december-19-2019-to-discuss-padcevtm\" target=\"_blank\">conference call</a> tomorrow, December 19, at 9:00 am ET to discuss the approval.</li><li>Shares up <font color=\"green\">6%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527294\" data-linked=\"FDA OKs Seattle Genetics ADC for urothelial cancer; shares up 6% after hours\" data-tweet=\"$SGEN $ALPMF $ALPMY - FDA OKs Seattle Genetics ADC for urothelial cancer; shares up 6% after hours https://seekingalpha.com/news/3527294-fda-oks-seattle-genetics-adc-for-urothelial-cancer-shares-up-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3527294-fda-oks-seattle-genetics-adc-for-urothelial-cancer-shares-up-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527283\" data-ts=\"1576708399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527283-mu-pcg-gdot-and-derm-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MU, PCG, GDOT and DERM among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/REVG' title='REV Group, Inc.'>REVG</a> <font color=\"green\">+6.9%</font>. <a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a> <font color=\"green\">+3.4%</font>. <a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"green\">+2.2%</font>. <a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a> <font color=\"green\">+2.8%</font>. <a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a> <font color=\"green\">+1.1%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a> <font color=\"red\">-24.9%</font>.<strong> </strong><a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a> <font color=\"red\">-8.4%</font>. <a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a> <font color=\"red\">-6.6%</font>. <a href='https://seekingalpha.com/symbol/CURR' title='CURE Pharmaceutical Holding Corp.'>OTCQB:CURR</a> <font color=\"red\">-4.6%. </font><a href='https://seekingalpha.com/symbol/ABM' title='ABM Industries Incorporated'>ABM</a> <font color=\"red\">-4.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527283\" data-linked=\"MU, PCG, GDOT and DERM among after hour movers\" data-tweet=\"$REVG $MU $PCG - MU, PCG, GDOT and DERM among after hour movers https://seekingalpha.com/news/3527283-mu-pcg-gdot-and-derm-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527283-mu-pcg-gdot-and-derm-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527266\" data-ts=\"1576706127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527266-western-digital-gains-after-micron-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital gains after Micron beats</a></h4><ul><li>Western Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) shares are <font color=\"green\">up 2.8%</font> following peer Micron's <a href=\"https://seekingalpha.com/news/3527257-micronplus-3-on-beats-in-line-revenue-outlook\" target=\"_blank\">earnings beat</a>.</li><li>Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) shares are <font color=\"green\">up 0.2%</font> to $57.28.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527266\" data-linked=\"Western Digital gains after Micron beats\" data-tweet=\"$WDC $INTC - Western Digital gains after Micron beats https://seekingalpha.com/news/3527266-western-digital-gains-after-micron-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3527266-western-digital-gains-after-micron-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527259\" data-ts=\"1576705098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NERV\" target=\"_blank\">NERV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527259-minervas-minminus-117-flunks-mid-stage-depression-study-shares-down-27-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Minerva&#39;s MIN-117 flunks mid-stage depression study; shares down 27% AH</a></h4><ul><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03446846?spons=minerva&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2b clinical trial</a> evaluating Minerva Neurosciences' (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) MIN-117 in adults with moderate-to-severe major depressive disorder &#40;MDD&#41; <a href=\"https://seekingalpha.com/pr/17732299-minerva-neurosciences-reports-topline-results-from-phase-2b-trial-of-minminus-117-in-major\" target=\"_blank\">failed to achieve</a> the primary endpoint and key secondary endpoints.</li><li>Neither dose tested adequately separated from placebo as measured by the reduction in MDD symptoms or anxiety symptoms over the six-week treatment period.</li><li>The company plans to terminate further development.</li><li><a href=\"http://www.minervaneurosciences.com/innovation-pipeline/min-117/\" target=\"_blank\">MIN-117</a> blocks a subtype of serotonin receptor called 5-HT1A. When blocked, anxiety and mood can be regulated.</li><li>Management will host a conference call at 5:00 pm ET to discuss the results.</li><li>Shares down <font color=\"red\">27%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527259\" data-linked=\"Minerva&#39;s MIN-117 flunks mid-stage depression study; shares down 27% AH\" data-tweet=\"$NERV - Minerva&#39;s MIN-117 flunks mid-stage depression study; shares down 27% AH https://seekingalpha.com/news/3527259-minervas-minminus-117-flunks-mid-stage-depression-study-shares-down-27-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3527259-minervas-minminus-117-flunks-mid-stage-depression-study-shares-down-27-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527261\" data-ts=\"1576705017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDOT\" target=\"_blank\">GDOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527261-green-dotminus-1_4-revenue-outlook-disappoints-ceo-and-cfo-to-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Green Dot -1.4% as revenue outlook disappoints; CEO and CFO to exit</a></h4><ul><li>Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">drops 1.4%</font> in after-hours trading after saying it<a href=\"https://seekingalpha.com/pr/17732325-green-dot-corporation-announces-retirement-of-founder-ceo-steve-streit\" target=\"_blank\"> expects 2019 non-GAAP total operating revenue </a>at the low end of its previous range of $1.06B-$1.08B.</li><li>Compares with consensus of $1.08B.</li><li>Also sees full-year adjusted EBITDA at low end of its previous range of $240M-$244M.</li><li>Sees 2019 non-GAAP EPS at ~$2.73, in line with its previous guidance range of $2.71-$2.77.</li><li>Green Dot's CEO and founder, Steve Street, will retire at the end of the month; he'll also retire from Green Dot's holding company board and as chairman of the Green Dot Bank board.</li><li>Green Dot board Chairman William I. Jacobs will serve as interim CEO and J. Christopher Brewster, chair of the audit committee, will serve as interim president.</li><li>At the same time, CFO Mark Shifke will retire and Jess Unruh, operational CFO and chief accounting officer, will serve as interim CFO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527261\" data-linked=\"Green Dot -1.4% as revenue outlook disappoints; CEO and CFO to exit\" data-tweet=\"$GDOT - Green Dot -1.4% as revenue outlook disappoints; CEO and CFO to exit https://seekingalpha.com/news/3527261-green-dotminus-1_4-revenue-outlook-disappoints-ceo-and-cfo-to-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3527261-green-dotminus-1_4-revenue-outlook-disappoints-ceo-and-cfo-to-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527257\" data-ts=\"1576704724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527257-micronplus-3-on-beats-in-line-revenue-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron +3% on beats, in-line revenue outlook</a></h4><ul><li>Update with DRAM and NAND outlook:</li><li>DRAM: For CY19, Micron expects bit supply demand to come in below the industry's mid-teens percentage forecast. In CY20, Micron's supply growth should come in slightly above the industry.</li><li>NAND: CY19 bit supply growth should be slightly below the mid-40% range for the industry. CY20 supply growth is expected \"meaningfully below\" industry supply growth, but bit shipment growth should be inline with the industry.</li><li>Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) <font color=\"green\">+3.3%</font> <a href=\"https://seekingalpha.com/news/3527227-micron-technology-eps-beats-0_01-beats-on-revenue\" target=\"_blank\">beats Q1 estimates</a> with revenue down 35% Y/Y. The Q2 outlook has in-line revenue of $4.5-4.8B (consensus: $4.77B) and downside EPS of $0.29-0.41 (consensus: $0.41).</li><li>Q1 gross margin was 27.3% compared to the 26.8% estimate.</li><li>Operating cash flow was $2.01B versus the $4.81B in last year's quarter.</li><li>Huawei: Micron says it received all requested licenses to support certain Huawei products not on the banned list.</li><li>MU is also licensed to qualify new products for Huawei's mobile and server businesses.</li><li>Micron doesn't expect a material revenue impact in the next couple of quarters.</li><li>Earnings call starts at 4:30 PM with a webcast <a href=\"https://seekingalpha.com/news/3527227-micron-technology-eps-beats-0_01-beats-on-revenue\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17732278-micron-technology-inc-reports-results-for-first-quarter-of-fiscal-2020\" target=\"_blank\">Press release</a> / <a href=\"https://seekingalpha.com/article/4313227-micron-technology-inc-2020-q1-results-earnings-call-presentation\" target=\"_blank\">Earnings presentation</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527257\" data-linked=\"Micron +3% on beats, in-line revenue outlook\" data-tweet=\"$MU - Micron +3% on beats, in-line revenue outlook https://seekingalpha.com/news/3527257-micronplus-3-on-beats-in-line-revenue-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3527257-micronplus-3-on-beats-in-line-revenue-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>199&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527251\" data-ts=\"1576704110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REVG\" target=\"_blank\">REVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527251-rev-groupplus-9-after-sales-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">REV Group +9% after sales beat</a></h4><ul> <li>REV Group (NYSE:<a href='https://seekingalpha.com/symbol/REVG' title='REV Group, Inc.'>REVG</a>) is higher despite reporting a drop in EPS to $0.05 in <a href=\"https://seekingalpha.com/pr/17732328-rev-group-inc-reports-fiscal-2019-fourth-quarter-and-full-year-results\" target=\"_blank\">FQ4</a> from $0.28 a year ago and $0.13 consensus off a 1% decline in sales. That sales drip was still ahead of the consensus estimate.</li> <li>Lower recreation segment shipments during the quarter was only partially offset by sales growth in the commercial and fire &amp; emergency segments.</li> <li>The company reports adjusted EBITDA of $19.3M vs. $23.3M consensus. The EBITDA mark is down 51% from a year ago.</li> <li>CEO update: \"Our businesses navigated tight labor markets and trade concerns to deliver results that would have been in the middle of our revised guidance range, absent the abnormally high health care cost experienced in the fourth quarter.\"</li> <li>Shares of REVG are <font color=\"green\">up 9.42%</font> AH to $12.89 on thin volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527248-rev-group-eps-misses-0_08-beats-on-revenue\" target=\"_blank\">REV Group EPS misses by $0.08, beats on revenue</a> (Dec. 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527251\" data-linked=\"REV Group +9% after sales beat\" data-tweet=\"$REVG - REV Group +9% after sales beat https://seekingalpha.com/news/3527251-rev-groupplus-9-after-sales-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3527251-rev-groupplus-9-after-sales-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527240\" data-ts=\"1576703678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527240-fcc-will-decide-on-intelsat-spectrum-payout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FCC will decide on Intelsat spectrum payout</a></h4><ul><li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) and SES <a href=\"https://www.bloomberg.com/news/articles/2019-12-18/intelsat-spectrum-payout-stalls-in-congress-pushing-it-to-fcc\" target=\"_blank\">might have to wait</a> for the FCC to decide their compensation for diverting some airwaves to mobile users.</li><li>Earlier this week, Congress failed to pass a measure that would let the companies share in almost half of the revenue expected from the airwaves sale.</li><li>The FCC can now decide on whether the companies get paid and how much. Chairman Ajit Pai hasn't publicly commented on whether the companies will receive any money.</li><li>Intelsat shares closed today <font color=\"green\">up 8.9%</font> to $6.49.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527240\" data-linked=\"FCC will decide on Intelsat spectrum payout\" data-tweet=\"$I - FCC will decide on Intelsat spectrum payout https://seekingalpha.com/news/3527240-fcc-will-decide-on-intelsat-spectrum-payout?source=tweet\" data-url=\"https://seekingalpha.com/news/3527240-fcc-will-decide-on-intelsat-spectrum-payout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527237\" data-ts=\"1576703343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527237-axsome-therapeutics-readies-equity-offering-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome Therapeutics readies equity offering; shares down 2% after hours</a></h4><ul><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) slips <font color=\"red\">2%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17732283-axsome-therapeutics-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527237\" data-linked=\"Axsome Therapeutics readies equity offering; shares down 2% after hours\" data-tweet=\"$AXSM - Axsome Therapeutics readies equity offering; shares down 2% after hours https://seekingalpha.com/news/3527237-axsome-therapeutics-readies-equity-offering-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3527237-axsome-therapeutics-readies-equity-offering-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527229\" data-ts=\"1576703067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NERV\" target=\"_blank\">NERV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527229-minerva-neurosciences-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Minerva Neurosciences shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527229\" data-linked=\"Minerva Neurosciences shares halted pending news\" data-tweet=\"$NERV - Minerva Neurosciences shares halted pending news https://seekingalpha.com/news/3527229-minerva-neurosciences-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3527229-minerva-neurosciences-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527227\" data-ts=\"1576702961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527227-micron-technology-eps-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron Technology EPS beats by $0.01, beats on revenue</a></h4><ul><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>): Q1 Non-GAAP EPS of $0.48 <font color=\"green\">beats by $0.01</font>; GAAP EPS of $0.43 <font color=\"green\">beats by $0.03</font>.</li><li>Revenue of $5.14B (-35.0% Y/Y) <font color=\"green\">beats by $100M</font>.</li><li>Shares <font color=\"green\">+3.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17732278-micron-technology-inc-reports-results-for-first-quarter-of-fiscal-2020\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527227\" data-linked=\"Micron Technology EPS beats by $0.01, beats on revenue\" data-tweet=\"$MU - Micron Technology EPS beats by $0.01, beats on revenue https://seekingalpha.com/news/3527227-micron-technology-eps-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527227-micron-technology-eps-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>99&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527221\" data-ts=\"1576701029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527221-uber-expanding-works-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber expanding its Works program</a></h4><ul><li>Uber (NYSE:<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a>) plans to expand its Uber Works pilot program, according to <a href=\"https://www.bloomberg.com/news/articles/2019-12-18/uber-works-app-expands-to-miami-for-cooking-and-cleaning-jobs\" target=\"_blank\">Bloomberg</a>.</li><li>Works connects workers and businesses offering short-term jobs in a variety of sectors, including hospitality, events, and light industrial.</li><li>Uber has been testing Works in Chicago and will next expand to Miami before moving to additional cities next year.</li><li>The program was sourcing workers from traditional temp agencies, but Uber wants to start recruiting from its driver pool.</li><li>Uber shares are <font color=\"green\">up 1%</font> to $30.05.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527221\" data-linked=\"Uber expanding its Works program\" data-tweet=\"$UBER - Uber expanding its Works program https://seekingalpha.com/news/3527221-uber-expanding-works-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3527221-uber-expanding-works-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527217\" data-ts=\"1576700189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527217-epizyme-up-12-after-advisory-committee-nod-on-tazemetostat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme up 12% after advisory committee nod on tazemetostat</a></h4><ul><li>Epizyme (<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme, Inc.'>EPZM</a> <font color=\"green\">+11.7%</font>) touched $25.00 (<font color=\"green\">+37%</font>) after trading resumed following the FDA advisory committee meeting on tazemetostat but could hold the gain. Volume is closing in on 1.6M shares, up two-fold.</li><li>In an unanimous 11-0 vote, the committee <a href=\"https://seekingalpha.com/news/3527180-fda-advisory-committee-backs-epizymes-tazemetostat\" target=\"_blank\">backed approval</a> for epithelioid sarcoma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527217\" data-linked=\"Epizyme up 12% after advisory committee nod on tazemetostat\" data-tweet=\"$EPZM - Epizyme up 12% after advisory committee nod on tazemetostat https://seekingalpha.com/news/3527217-epizyme-up-12-after-advisory-committee-nod-on-tazemetostat?source=tweet\" data-url=\"https://seekingalpha.com/news/3527217-epizyme-up-12-after-advisory-committee-nod-on-tazemetostat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527216\" data-ts=\"1576699611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527216-inpixon-and-streamline-health-solutions-among-tech-gainers-nanthealth-and-communications\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Inpixon and Streamline Health Solutions among Tech gainers; NantHealth and Communications Systems among losers</a></h4><ul><li><b>Gainers: </b>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+45%</font>. Streamline Health Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a>) <font color=\"green\">+18%</font>. Glowpoint (NYSEMKT:<a href='https://seekingalpha.com/symbol/GLOW' title='Glowpoint, Inc.'>GLOW</a>) <font color=\"green\">+17%</font>. YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"green\">+17%</font>. 10x Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/TXG' title='10x Genomics, Inc.'>TXG</a>) <font color=\"green\">+13%</font>.</li><li><b>Losers: </b>NantHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/NH' title='NantHealth, Inc.'>NH</a>) <font color=\"red\">-12%</font>. Communications Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/JCS' title='Communications Systems, Inc.'>JCS</a>) <font color=\"red\">-9%</font>. Boxlight (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight Corporation'>BOXL</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527216\" data-linked=\"Inpixon and Streamline Health Solutions among Tech gainers; NantHealth and Communications Systems among losers\" data-tweet=\"$INPX $STRM $GLOW - Inpixon and Streamline Health Solutions among Tech gainers; NantHealth and Communications Systems among losers https://seekingalpha.com/news/3527216-inpixon-and-streamline-health-solutions-among-tech-gainers-nanthealth-and-communications?source=tweet\" data-url=\"https://seekingalpha.com/news/3527216-inpixon-and-streamline-health-solutions-among-tech-gainers-nanthealth-and-communications\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527215\" data-ts=\"1576699463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527215-skyworks-qorvo-broadcom-mulls-rf-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyworks, Qorvo as Broadcom mulls RF sale</a></h4><ul><li>RF chipmakers Skyworks (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>)<font color=\"green\"> gains 2.2%</font> and Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc.'>QRVO</a>) <font color=\"green\">gains 0.8%</font> after the <a href=\"https://seekingalpha.com/news/3527200-broadcom-wants-buyer-for-rf-unit-wsj\" target=\"_blank\">WSJ report </a>that Broadcom is seeking a buyer for its RF unit.</li><li>Broadcom is still in early talks, and the details can still change.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527215\" data-linked=\"Skyworks, Qorvo as Broadcom mulls RF sale\" data-tweet=\"$SWKS $QRVO - Skyworks, Qorvo as Broadcom mulls RF sale https://seekingalpha.com/news/3527215-skyworks-qorvo-broadcom-mulls-rf-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3527215-skyworks-qorvo-broadcom-mulls-rf-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527209\" data-ts=\"1576697474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATVI\" target=\"_blank\">ATVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527209-atvi-calls-modern-warfare-played-in-series\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ATVI calls &#39;Modern Warfare&#39; most played in series</a></h4><ul><li>Activision Blizzard (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a>) says <em>Call of Duty: Modern Warfare</em> is the most played<em> Call of Duty</em> game of this console generation.</li><li>ATVI says Modern Warfare has crossed $1B in global sell-through, over 500M multiplayer hours played, and nearly 300M multiplayer matches.</li><li>Activision shares are <font color=\"green\">up 1.1%</font> to $58.89.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527209\" data-linked=\"ATVI calls &#39;Modern Warfare&#39; most played in series\" data-tweet=\"$ATVI - ATVI calls &#39;Modern Warfare&#39; most played in series https://seekingalpha.com/news/3527209-atvi-calls-modern-warfare-played-in-series?source=tweet\" data-url=\"https://seekingalpha.com/news/3527209-atvi-calls-modern-warfare-played-in-series\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527208\" data-ts=\"1576696770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527208-tesla-cruises-to-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla cruises to all-time high</a></h4><ul> <li>Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+3.1%</font>) carved out a new intraday high of $390.84 today and is on pace for its best quarter since 2013 as some of the drama around the EV automaker has cooled off.</li> <li>The last time Tesla was dabbling with the $380-$390 level was when Elon Musk fired off his infamous \"funding secured\" tweet in August of 2018 and sent heads spinning.</li> <li>There is some talk with technical traders that Tesla is reaching a resistance point at which a breakout would be on the significant side either up or down. Miller Tabak is betting on the <a href=\"https://www.cnbc.com/2019/12/18/tesla-stock-is-at-records-but-charts-warn-of-danger-zone.html\" target=\"_blank\">downside</a>. \"It's going to have a tough time breaking out here, and especially as we move into the new year and get past this bullish Santa Claus season,\" observes Chief Market Strategist Matt Maley. Meanwhile, Bloomberg's William Maloney thinks the current long duration of the TSLA rally and wide trading range could suggest significant upside potential.</li> <li>Also of note with the EV stock, short interest on Tesla is off the levels from earlier this year, but still at a volume considered elevated.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527208\" data-linked=\"Tesla cruises to all-time high\" data-tweet=\"$TSLA - Tesla cruises to all-time high https://seekingalpha.com/news/3527208-tesla-cruises-to-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3527208-tesla-cruises-to-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>439&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527206\" data-ts=\"1576695785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527206-lsb-industries-and-u-s-silica-among-energy-materials-gainers-camber-energy-and-emx-royalty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LSB Industries and U.S. Silica among Energy/Materials gainers; Camber Energy and EMX Royalty among losers</a></h4><ul><li><b>Gainers: </b>LSB Industries (NYSE:<a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a>) <font color=\"green\">+11%</font>. U.S. Silica (NYSE:<a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica Holdings, Inc.'>SLCA</a>) <font color=\"green\">+11%</font>. San Juan Basin Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/SJT' title='San Juan Basin Royalty Trust'>SJT</a>) <font color=\"green\">+10%</font>. FTS International (NYSE:<a href='https://seekingalpha.com/symbol/FTSI' title='FTS International, Inc.'>FTSI</a>) <font color=\"green\">+10%</font>. Pacific Drilling (NYSE:<a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling S.A.'>PACD</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-12%</font>. EMX Royalty (NYSEMKT:<a href='https://seekingalpha.com/symbol/EMX' title='EMX Royalty Corporation'>EMX</a>) <font color=\"red\">-6%</font>. China Natural Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527206\" data-linked=\"LSB Industries and U.S. Silica among Energy/Materials gainers; Camber Energy and EMX Royalty among losers\" data-tweet=\"$LXU $SLCA $SJT - LSB Industries and U.S. Silica among Energy/Materials gainers; Camber Energy and EMX Royalty among losers https://seekingalpha.com/news/3527206-lsb-industries-and-u-s-silica-among-energy-materials-gainers-camber-energy-and-emx-royalty?source=tweet\" data-url=\"https://seekingalpha.com/news/3527206-lsb-industries-and-u-s-silica-among-energy-materials-gainers-camber-energy-and-emx-royalty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527205\" data-ts=\"1576695648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527205-suntrust-positive-on-saic-after-leidos-denial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust positive on SAIC after Leidos denial</a></h4><ul><li>The U.S. Government Accountability Office denied the Leidos protest related to the $78M Air Force contract for cloud migration.</li><li>SunTrust analyst Tobey Sommer sees this as a \"strong takeaway win\" for contract winner SAIC.</li><li>Sommer notes that SAIC is still awaiting a recompete award decision for its $1.8B DOJ Asset Forfeiture contract.</li><li>SunTrust rates SAIC at Buy and a $100 target. The company has a Bullish average<a href=\"https://seekingalpha.com/symbol/SAIC/ratings/sell-side-ratings\" target=\"_blank\"> Sell Side rating</a>.</li><li>SAIC shares are <font color=\"green\">up 1%</font> to $84.85.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527205\" data-linked=\"SunTrust positive on SAIC after Leidos denial\" data-tweet=\"SunTrust positive on SAIC after Leidos denial https://seekingalpha.com/news/3527205-suntrust-positive-on-saic-after-leidos-denial?source=tweet\" data-url=\"https://seekingalpha.com/news/3527205-suntrust-positive-on-saic-after-leidos-denial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527203\" data-ts=\"1576694981\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOYA\" target=\"_blank\">VOYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527203-voyaplus-6_7-deal-beats-credit-suisse-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Voya +6.7% as deal beats Credit Suisse expectations</a></h4><ul><li>Voya Financial (NYSE:<a href='https://seekingalpha.com/symbol/VOYA' title='Voya Financial, Inc.'>VOYA</a>) <font color=\"green\">surges 6.7% </font>after Credit Suisse analyst Andrew Kligerman points out that its sale of its Individual Life business will produce $1.7B of proceeds, more than the company's targeted $1B+ in cash return from the unit by 2024.</li><li>Voya's guidance for at least $1B of share repurchases next year exceeds Kligerman's estimate of $750M.</li><li>Describes Voya's retained businesses as \"capital-light and poised for growth.\"</li><li>Repeats outperform recommendation and raises price target to Street-high $72 from $66.</li><li><a href=\"https://seekingalpha.com/symbol/VOYA/ratings/quant-ratings\" target=\"_blank\">Quant rating</a> for Voya is Neutral; <a href=\"https://seekingalpha.com/symbol/VOYA/ratings/sell-side-ratings\" target=\"_blank\">Sell-Side average rating</a> is Bullish (6 Very Bullish, 5 Bullish, 3 Neutral, 1 Bearish).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527016-voya-to-divest-individual-life-business-closed-blocks-for-1_7b\" target=\"_blank\">Voya to divest individual life business, other closed blocks for $1.7B</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3527203\" data-linked=\"Voya +6.7% as deal beats Credit Suisse expectations\" data-tweet=\"$VOYA - Voya +6.7% as deal beats Credit Suisse expectations https://seekingalpha.com/news/3527203-voyaplus-6_7-deal-beats-credit-suisse-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3527203-voyaplus-6_7-deal-beats-credit-suisse-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527200\" data-ts=\"1576694656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527200-broadcom-wants-buyer-for-rf-unit-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom wants buyer for RF unit - WSJ</a></h4><ul><li>Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) is working with Credit Suisse to find a buyer for its RF unit, according to <a href=\"https://www.wsj.com/articles/broadcom-seeks-buyer-for-rf-wireless-chip-unit-11576693454\" target=\"_blank\">WSJ sources</a>.</li><li>The unit had $2.2B in revenue in FY19.</li><li>Sources say the unit could be worth $10B.</li><li>The talks are in the early stages, and details could change.</li><li>During last week's <a href=\"https://seekingalpha.com/article/4312278-broadcom-inc-avgo-ceo-hock-tan-on-q4-2019-results-earnings-call-transcript\" target=\"_blank\">earnings repor</a>t, Broadcom said it would reclassify its wireless units outside its core semi business.</li><li>Broadcom shares are <font color=\"green\">up 1.8%</font> to $329.56.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527200\" data-linked=\"Broadcom wants buyer for RF unit - WSJ\" data-tweet=\"$AVGO - Broadcom wants buyer for RF unit - WSJ https://seekingalpha.com/news/3527200-broadcom-wants-buyer-for-rf-unit-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3527200-broadcom-wants-buyer-for-rf-unit-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527196\" data-ts=\"1576693936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527196-strong-ad-spend-ahead-for-facebook-deutsche\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong ad spend ahead for Facebook - Deutsche</a></h4><ul><li>Deutsche Bank analyst Lloyd Walmsley says Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook, Inc.'>FB</a>) should see a strong year for ad spending in 2020.</li><li>The analyst is \"more upbeat on core Facebook and the eCommerce opportunity at Instagram\" after meeting with a digital ad executive.</li><li>Walmsley raises his Facebook price target from $260 to $270, matching the Street-high PT.</li><li>The analyst also weighs in on Snapchat (<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='green'>+0.6%</font>), saying the company will face its first period of tougher comps next year, and Pinterest (<a href='https://seekingalpha.com/symbol/PINS' title='Pinterest, Inc.'>PINS</a> <font color='green'>+2.4%</font>), which has an \"elevated\" execution risk because of its \"history of moving somewhat slowly.\"</li><li>Facebook shares are <font color=\"green\">up 2.1%</font> to $202.58.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527196\" data-linked=\"Strong ad spend ahead for Facebook - Deutsche\" data-tweet=\"$FB $SNAP $PINS - Strong ad spend ahead for Facebook - Deutsche https://seekingalpha.com/news/3527196-strong-ad-spend-ahead-for-facebook-deutsche?source=tweet\" data-url=\"https://seekingalpha.com/news/3527196-strong-ad-spend-ahead-for-facebook-deutsche\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527192\" data-ts=\"1576692385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTC-USD\" target=\"_blank\">BTC-USD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527192-bitcoin-takes-up-residence-below-7k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin takes up residence below $7K</a></h4><ul><li>A new leg down in Bitcoin's (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) bear move brought the crypto to a $6-handle a few days back. Despite a <font color=\"green\">near-4% bounce</font> today, Bitcoin currently is changing hands at about $130 below the $7K level.</li><li>Some technicians <a href=\"https://www.coindesk.com/bitcoin-drops-below-major-price-support-for-first-time-since-may\" target=\"_blank\">are looking at the</a> 200-day moving average, and note the recent dip brought Bitcoin below that for the first since May. They're eyeing a coming possible break of the $6.5K level.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527192\" data-linked=\"Bitcoin takes up residence below $7K\" data-tweet=\"$BTC-USD - Bitcoin takes up residence below $7K https://seekingalpha.com/news/3527192-bitcoin-takes-up-residence-below-7k?source=tweet\" data-url=\"https://seekingalpha.com/news/3527192-bitcoin-takes-up-residence-below-7k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527190\" data-ts=\"1576692181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527190-uniti-group-and-banco-macro-among-financial-gainers-qiwi-and-china-internet-nationwide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uniti Group and Banco Macro among Financial gainers; Qiwi and China Internet Nationwide Financial Services among losers</a></h4><ul><li><b>Gainers: </b>Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) <font color=\"green\">+15%</font>. Banco Macro (NYSE:<a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a>) <font color=\"green\">+7%</font>. Voya Financial (NYSE:<a href='https://seekingalpha.com/symbol/VOYA' title='Voya Financial, Inc.'>VOYA</a>) <font color=\"green\">+7%</font>. Leaf Group (NYSE:<a href='https://seekingalpha.com/symbol/LEAF' title='Leaf Group Ltd.'>LEAF</a>) <font color=\"green\">+6%</font>. Banco BBVA Argentina (NYSE:<a href='https://seekingalpha.com/symbol/BBAR' title='Banco BBVA Argentina S.A.'>BBAR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Qiwi (NASDAQ:<a href='https://seekingalpha.com/symbol/QIWI' title='Qiwi plc'>QIWI</a>) <font color=\"red\">-13%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"red\">-8%</font>. Dunxin Financial (NYSEMKT:<a href='https://seekingalpha.com/symbol/DXF' title='Dunxin Financial Holdings Limited'>DXF</a>) <font color=\"red\">-6%</font>. eHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/EHTH' title='eHealth, Inc.'>EHTH</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527190\" data-linked=\"Uniti Group and Banco Macro among Financial gainers; Qiwi and China Internet Nationwide Financial Services among losers\" data-tweet=\"$UNIT $BMA $VOYA - Uniti Group and Banco Macro among Financial gainers; Qiwi and China Internet Nationwide Financial Services among losers https://seekingalpha.com/news/3527190-uniti-group-and-banco-macro-among-financial-gainers-qiwi-and-china-internet-nationwide?source=tweet\" data-url=\"https://seekingalpha.com/news/3527190-uniti-group-and-banco-macro-among-financial-gainers-qiwi-and-china-internet-nationwide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527189\" data-ts=\"1576692068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527189-argan-among-industrial-gainers-toro-and-lennox-international-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argan among industrial gainers; Toro and Lennox International among losers</a></h4><ul><li><b>Gainers: </b>Concrete Pumping (NASDAQ:<a href='https://seekingalpha.com/symbol/BBCP' title='Concrete Pumping Holdings, Inc.'>BBCP</a>) <font color=\"green\">+9%</font>. Argan (NYSE:<a href='https://seekingalpha.com/symbol/AGX' title='Argan, Inc.'>AGX</a>) <font color=\"green\">+7%</font>. Loma Negra Compania (NYSE:<a href='https://seekingalpha.com/symbol/LOMA' title='Loma Negra Compañía Industrial Argentina Sociedad Anónima'>LOMA</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"red\">-19%</font>. The Dixie (NASDAQ:<a href='https://seekingalpha.com/symbol/DXYN' title='The Dixie Group, Inc.'>DXYN</a>) <font color=\"red\">-9%</font>. The Toro (NYSE:<a href='https://seekingalpha.com/symbol/TTC' title='The Toro Company'>TTC</a>) <font color=\"red\">-8%</font>. Lennox International (NYSE:<a href='https://seekingalpha.com/symbol/LII' title='Lennox International Inc.'>LII</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527189\" data-linked=\"Argan among industrial gainers; Toro and Lennox International among losers\" data-tweet=\"$BBCP $AGX $LOMA - Argan among industrial gainers; Toro and Lennox International among losers https://seekingalpha.com/news/3527189-argan-among-industrial-gainers-toro-and-lennox-international-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527189-argan-among-industrial-gainers-toro-and-lennox-international-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527187\" data-ts=\"1576691955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STRM\" target=\"_blank\">STRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527187-streamline-health-to-sell-ecm-business-shares-up-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Streamline Health to sell ECM business; shares up 24%</a></h4><ul><li>Thinly traded nano cap Streamline Health Solutions (<a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a> <font color=\"green\">+23.9%</font>) has <a href=\"https://seekingalpha.com/pr/17731748-streamline-health-r-announces-signing-of-definitive-agreement-to-sell-enterprise-content\" target=\"_blank\">agreed to sell</a> its legacy Enterprise Content Management &#40;ECM&#41; business to Hyland of Westlake, OH for an undisclosed sum. The transaction should close by the end of next month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527187\" data-linked=\"Streamline Health to sell ECM business; shares up 24%\" data-tweet=\"$STRM - Streamline Health to sell ECM business; shares up 24% https://seekingalpha.com/news/3527187-streamline-health-to-sell-ecm-business-shares-up-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3527187-streamline-health-to-sell-ecm-business-shares-up-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527186\" data-ts=\"1576691525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNO\" target=\"_blank\">VNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527186-vornadoplus-2_4-after-special-dividend-declared\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vornado +2.4% after special dividend declared</a></h4><ul><li>Vornado Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/VNO' title='Vornado Realty Trust'>VNO</a>)<font color=\"green\"> jumps 2.4%</font> after the REIT <a href=\"https://seekingalpha.com/pr/17732044-vornado-declares-special-dividend-of-1_95-per-share\" target=\"_blank\">declares a special dividend</a> of $1.95 per share.</li><li>The dividend is the result of gains from the transfer of a 45.4% common equity interest in its flagship high street retail assets on upper Fifth Avenue and Times Square, the sale of its 25% interest in 330 Madison Avenue and other previously disclosed asset sales, partly offset by a tax deduction resulting from its former investment in Toys R Us.</li><li>About $1.74 of the special dividend will be long-term capital gain.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527186\" data-linked=\"Vornado +2.4% after special dividend declared\" data-tweet=\"$VNO - Vornado +2.4% after special dividend declared https://seekingalpha.com/news/3527186-vornadoplus-2_4-after-special-dividend-declared?source=tweet\" data-url=\"https://seekingalpha.com/news/3527186-vornadoplus-2_4-after-special-dividend-declared\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527185\" data-ts=\"1576690904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527185-ctic-akrx-qiwi-and-inpx-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTIC, AKRX, QIWI and INPX among midday movers</a></h4><ul><li><strong>Gainers: </strong>Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"green\">+68%</font>.</li><li>Mirum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MIRM' title='Mirum Pharmaceuticals, Inc.'>MIRM</a>) <font color=\"green\">+53%</font>.</li><li>YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"green\">+30%</font>.</li><li>Naked Brand (NASDAQ:<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a>) <font color=\"green\">+28%</font>.</li><li>IGM Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/IGMS' title='IGM Biosciences, Inc.'>IGMS</a>) <font color=\"green\">+29%</font>.</li><li>Streamline Health Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/STRM' title='Streamline Health Solutions, Inc.'>STRM</a>) <font color=\"green\">+27%</font>.</li><li>LAIX (NYSE:<a href='https://seekingalpha.com/symbol/LAIX' title='LAIX Inc.'>LAIX</a>) <font color=\"green\">+23%</font>.</li><li>Galera Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GRTX' title='Galera Therapeutics, Inc.'>GRTX</a>) <font color=\"green\">+23%</font>.</li><li>Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals, Inc.'>SYRS</a>) <font color=\"green\">+21%</font>.</li><li>Fluent (NASDAQ:<a href='https://seekingalpha.com/symbol/FLNT' title='Fluent, Inc.'>FLNT</a>) <font color=\"green\">+20%</font>.</li><li><strong>Losers: </strong>Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) <font color=\"red\">-35%</font>.</li><li>Trans World Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corporation'>TWMC</a>) <font color=\"red\">-21%</font>.</li><li>Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences Inc.'>SLDB</a>) <font color=\"red\">-17%</font>.</li><li>Allakos (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLK' title='Allakos Inc.'>ALLK</a>) <font color=\"red\">-15%</font>.</li><li>CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) <font color=\"red\">-14%</font>.</li><li>Qiwi (NASDAQ:<a href='https://seekingalpha.com/symbol/QIWI' title='Qiwi plc'>QIWI</a>) <font color=\"red\">-13%</font>.</li><li>Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a>) <font color=\"red\">-12%</font>.</li><li>PDS Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PDSB' title='PDS Biotechnology Corporation'>PDSB</a>) <font color=\"red\">-12%</font>.</li><li>Communications Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/JCS' title='Communications Systems, Inc.'>JCS</a>) <font color=\"red\">-11%</font>.</li><li>Independence Contract Drilling (NYSE:<a href='https://seekingalpha.com/symbol/ICD' title='Independence Contract Drilling, Inc.'>ICD</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527185\" data-linked=\"CTIC, AKRX, QIWI and INPX among midday movers\" data-tweet=\"$INPX $MIRM $YAYO - CTIC, AKRX, QIWI and INPX among midday movers https://seekingalpha.com/news/3527185-ctic-akrx-qiwi-and-inpx-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527185-ctic-akrx-qiwi-and-inpx-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527182\" data-ts=\"1576690458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLK\" target=\"_blank\">ALLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527182-allakos-down-16-on-bearish-seligman-research-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allakos down 16% on bearish Seligman Research report</a></h4><ul><li>Therapeutic antibody developer Allakos (<a href='https://seekingalpha.com/symbol/ALLK' title='Allakos Inc.'>ALLK</a> <font color=\"red\">-15.7%</font>) is down on almost double normal volume in apparent response to a stream of <a href=\"https://twitter.com/seligmanrsrch\" target=\"_blank\">bearish tweets</a> from Seligman Research related to its just-published report.</li><li>The fundamental research shop cites 22 red flags including the lack of KOL validation, minimum sell-side coverage for a company this size, the failure of AK001 (precursor to AK002) and questionable clinical data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527182\" data-linked=\"Allakos down 16% on bearish Seligman Research report\" data-tweet=\"$ALLK - Allakos down 16% on bearish Seligman Research report https://seekingalpha.com/news/3527182-allakos-down-16-on-bearish-seligman-research-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3527182-allakos-down-16-on-bearish-seligman-research-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527180\" data-ts=\"1576689656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527180-fda-advisory-committee-backs-epizymes-tazemetostat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA advisory committee backs Epizyme&#39;s tazemetostat</a></h4><ul><li>The FDA's Oncologic Drugs Advisory Committee voted 11-0 that the benefits of Epizyme's (<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme, Inc.'>EPZM</a>) tazemetostat outweigh the risks for the treatment of epithelioid sarcoma.</li><li>Shares remain halted.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527180\" data-linked=\"FDA advisory committee backs Epizyme&#39;s tazemetostat\" data-tweet=\"$EPZM - FDA advisory committee backs Epizyme&#39;s tazemetostat https://seekingalpha.com/news/3527180-fda-advisory-committee-backs-epizymes-tazemetostat?source=tweet\" data-url=\"https://seekingalpha.com/news/3527180-fda-advisory-committee-backs-epizymes-tazemetostat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527174\" data-ts=\"1576688418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527174-steelcase-leads-consumer-gainers-davidstea-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelcase leads consumer gainers; DAVIDsTEA among losers</a></h4><ul><li><b>Gainers: </b>Steelcase (NYSE:<a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a>) <font color=\"green\">+18%</font>. Naked Brand (NASDAQ:<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a>) <font color=\"green\">+18%</font>. Nautilus (NYSE:<a href='https://seekingalpha.com/symbol/NLS' title='Nautilus, Inc.'>NLS</a>) <font color=\"green\">+13%</font>. The Lovesac (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"green\">+8%</font>. Tandy Leather Factory (NASDAQ:<a href='https://seekingalpha.com/symbol/TLF' title='Tandy Leather Factory, Inc.'>TLF</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Hyster-Yale Materials (NYSE:<a href='https://seekingalpha.com/symbol/HY' title='Hyster-Yale Materials Handling, Inc.'>HY</a>) <font color=\"red\">-9%</font>. DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDsTEA Inc.'>DTEA</a>) <font color=\"red\">-6%</font>. Celsius (NASDAQ:<a href='https://seekingalpha.com/symbol/CELH' title='Celsius Holdings, Inc.'>CELH</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527174\" data-linked=\"Steelcase leads consumer gainers; DAVIDsTEA among losers\" data-tweet=\"$SCS $NAKD $NLS - Steelcase leads consumer gainers; DAVIDsTEA among losers https://seekingalpha.com/news/3527174-steelcase-leads-consumer-gainers-davidstea-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527174-steelcase-leads-consumer-gainers-davidstea-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527173\" data-ts=\"1576688289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KERN\" target=\"_blank\">KERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527173-akerna-purchases-ample-organics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akerna purchases Ample Organics</a></h4><ul><li>The cash and stock deal is valued at up to $45M - $5.7M in cash and $32.3M in Akerna (NASDAQ:<a href='https://seekingalpha.com/symbol/KERN' title='Akerna Corp.'>KERN</a>) stock, with additional consideration of $7.6M possible.</li><li>Ample is expecting 2020 revenue of $8.7M.</li><li>The deal is seen closing in Q1.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17732034-b-akerna-b-announces-acquisition-of-ample-organics\" target=\"_blank\">Press Release</a></li><li>Shares remain halted, <font color=\"red\">down 1.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527173\" data-linked=\"Akerna purchases Ample Organics\" data-tweet=\"$KERN - Akerna purchases Ample Organics https://seekingalpha.com/news/3527173-akerna-purchases-ample-organics?source=tweet\" data-url=\"https://seekingalpha.com/news/3527173-akerna-purchases-ample-organics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527169\" data-ts=\"1576687526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KERN\" target=\"_blank\">KERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527169-akerna-corp-halted-news-pending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akerna Corp halted with news pending</a></h4><ul><li><a href='https://seekingalpha.com/symbol/KERN' title='Akerna Corp.'>KERN</a> <font color=\"red\">down 1.4%</font> at time of the halt.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527169\" data-linked=\"Akerna Corp halted with news pending\" data-tweet=\"$KERN - Akerna Corp halted with news pending https://seekingalpha.com/news/3527169-akerna-corp-halted-news-pending?source=tweet\" data-url=\"https://seekingalpha.com/news/3527169-akerna-corp-halted-news-pending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527166\" data-ts=\"1576687211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTC\" target=\"_blank\">TTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527166-toro-company-down-8-post-q4-results-provides-fy20-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toro Company down 8% post Q4 results; provides FY20 guidance</a></h4><ul><li>Toro (<a href='https://seekingalpha.com/symbol/TTC' title='The Toro Company'>TTC</a> <font color=\"red\">-8.2%</font>) reported Q4 net sales growth of 36.2% Y/Y to $734.3M, and FY19 net sales growth of 19.8% Y/Y to $3.14B.</li><li>Segment sales: Professional $588.18M (+46.9% Y/Y); Residential $135.74M (+1.9% Y/Y); and Other $10.46M (+86.3% Y/Y).</li><li>Q4 Gross margin <font color=\"green\">expanded by 20 bps</font> to 33.4%; and operating margin <font color=\"red\">declined by 208 bps </font>to 5.9%.</li><li>Adj. gross margin <font color=\"green\">expanded by 132 bps</font> to 34.5%; and Adj. operating margin<font color=\"green\"> expanded by 44 bps</font> to 8.4%.</li><li>Net cash provided by operating activities for FY19 was $337.37M, compared to $374.81M year ago.</li><li>Accounts receivable were $268.8M (+39.1% Y/Y). Net inventories were $651.7M (+81.9% Y/Y). Accounts payable were $319.2M (+24.4% Y/Y).</li><li>For 1Q20 company expects Adj. EPS of about $0.58 per diluted share, vs $0.62 consensus.</li><li><strong>FY20 Outlook:</strong> Company expects Net sales of ~$3.6B; and Adj. EPS in range of $3.33 to $3.40.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527053-toro-eps-beats-0_03-misses-on-revenue\" target=\"_blank\">Toro EPS beats by $0.03, misses on revenue</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3527166\" data-linked=\"Toro Company down 8% post Q4 results; provides FY20 guidance\" data-tweet=\"$TTC - Toro Company down 8% post Q4 results; provides FY20 guidance https://seekingalpha.com/news/3527166-toro-company-down-8-post-q4-results-provides-fy20-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3527166-toro-company-down-8-post-q4-results-provides-fy20-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527165\" data-ts=\"1576686798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527165-s-and-p-moves-send-columbia-sportswear-uniti-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">S&amp;P moves send Columbia Sportswear, Uniti higher</a></h4><ul> <li>Columbia Sportswear (<a href='https://seekingalpha.com/symbol/COLM' title='Columbia Sportswear Company'>COLM</a> <font color=\"green\">+7.5%</font>) pops after the company is added to the S&amp;P Midcap 400 Index to replace Uniti Group (<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color=\"green\">+12.8%</font>), which is moving to the S&amp;P SmallCap 600 Index.</li> <li>Shares of Columbia Sportswear are back over $100 for the first time since late October, while Uniti is at a four-month high.</li> <li><a href=\"https://us.spindices.com/resource-center/press-room/\" target=\"_blank\">S&amp;P press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3527165\" data-linked=\"S&amp;P moves send Columbia Sportswear, Uniti higher\" data-tweet=\"$COLM $UNIT - S&amp;P moves send Columbia Sportswear, Uniti higher https://seekingalpha.com/news/3527165-s-and-p-moves-send-columbia-sportswear-uniti-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3527165-s-and-p-moves-send-columbia-sportswear-uniti-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527164\" data-ts=\"1576686631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKRX\" target=\"_blank\">AKRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527164-akorn-adds-to-selloff-down-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akorn adds to selloff, down 21%</a></h4><ul><li>Akorn (<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color=\"red\">-21.1%</font>) slumps on more than triple normal volume. Shares have sold off more than <font color=\"red\">32%</font> since Monday when it <a href=\"https://seekingalpha.com/pr/17728554-akorn-announces-extension-of-standstill-agreement\" target=\"_blank\">announced</a> an extension of its standstill agreement with lenders until February 7, 2020, to allow more time for it to evaluate strategic alternatives aimed primarily at addressing litigation-related liabilities. Investors appear wary that it may file for bankruptcy protection.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527164\" data-linked=\"Akorn adds to selloff, down 21%\" data-tweet=\"$AKRX - Akorn adds to selloff, down 21% https://seekingalpha.com/news/3527164-akorn-adds-to-selloff-down-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3527164-akorn-adds-to-selloff-down-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527163\" data-ts=\"1576686457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527163-zscaler-bull-sees-advantage-over-panw-zsplus-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zscaler bull sees advantage over PANW; ZS +2%</a></h4><ul><li>Berenberg says an internal survey shows that Zscaler's (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler, Inc.'>ZS</a>) technology \"is significantly ahead of Palo Alto (<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks, Inc.'>PANW</a> <font color='green'>+0.1%</font>) especially in regards to user experience and scalability,\"</li><li>The firm says Zscaler's \"best in class\" tech should help the company \"continue to drive strong sustainable top-line growth.\"</li><li>Berenberg maintains a Buy rating and $60 price target on ZS. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/ZS/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Zscaler shares are <font color=\"green\">up 2.3%</font> to $47.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527163\" data-linked=\"Zscaler bull sees advantage over PANW; ZS +2%\" data-tweet=\"$ZS $PANW - Zscaler bull sees advantage over PANW; ZS +2% https://seekingalpha.com/news/3527163-zscaler-bull-sees-advantage-over-panw-zsplus-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3527163-zscaler-bull-sees-advantage-over-panw-zsplus-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527162\" data-ts=\"1576686361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STAG\" target=\"_blank\">STAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527162-stag-industrialplus-1_4-rbc-boosts-to-top-pick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stag Industrial +1.4% as RBC boosts to top pick</a></h4><ul><li>Stag Industrial (NYSE:<a href='https://seekingalpha.com/symbol/STAG' title='STAG Industrial, Inc.'>STAG</a>)<font color=\"green\"> gains 1.4%</font> after RBC Capital Markets analyst Michael Carroll upgrades the stock to a top pick from outperform.</li><li>Notes that Stag is \"well positioned to deliver healthy earnings growth\" on improving organic growth and external trends.</li><li>Sees the REIT at attractive valuation vs. peers and adds that \"investment activity should remain elevated and drive healthy accretion.\"</li><li><a href=\"https://seekingalpha.com/symbol/STAG/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bullish; <a href=\"https://seekingalpha.com/symbol/STAG/ratings/sell-side-ratings\" target=\"_blank\">Sell-Side average rating</a> also Bullish (7 Very Bullish, 3 Bullish, 1 Neutral, 1 Bearish).</li><li><a href=\"https://seekingalpha.com/symbol/STAG/peers/comparison\" target=\"_blank\">Compare Stag's key stats</a> with those of its peers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527162\" data-linked=\"Stag Industrial +1.4% as RBC boosts to top pick\" data-tweet=\"$STAG - Stag Industrial +1.4% as RBC boosts to top pick https://seekingalpha.com/news/3527162-stag-industrialplus-1_4-rbc-boosts-to-top-pick?source=tweet\" data-url=\"https://seekingalpha.com/news/3527162-stag-industrialplus-1_4-rbc-boosts-to-top-pick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527159\" data-ts=\"1576685577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLCO\" target=\"_blank\">MLCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527159-melco-resorts-jumps-on-mix-of-positive-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Melco Resorts jumps on mix of positive news</a></h4><ul> <li>Melco Resorts &amp; Entertainment (<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited'>MLCO</a> <font color=\"green\">+2.6%</font>) rallies after the People's Bank of China stated it plans to lift the daily remittance limit on the transfer of money by individuals from Macau to mainland Chinese accounts.</li> <li>The casino stock was also singled out today by Nomura Instinet as one of its top picks for 2020.</li> <li>Nomura sets a price target of $33 on Buy-rated MLCO based off a sum-of-the-parts evaluation. The price target factors in  Macau EBITDA at 12X and City Of Dreams Manila EBITDA at 10X. The Nomura PT is above the <a href=\"https://seekingalpha.com/symbol/MLCO/ratings/sell-side-ratings\" target=\"_blank\">average sell-side price target</a> of $30.21.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527159\" data-linked=\"Melco Resorts jumps on mix of positive news\" data-tweet=\"$MLCO - Melco Resorts jumps on mix of positive news https://seekingalpha.com/news/3527159-melco-resorts-jumps-on-mix-of-positive-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3527159-melco-resorts-jumps-on-mix-of-positive-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527158\" data-ts=\"1576685562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISH\" target=\"_blank\">DISH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527158-dishplus-4-after-revealing-10b-in-network-financing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DISH +4% after revealing $10B in network financing</a></h4><ul><li>DISH Network (NASDAQ:<a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a>) is <font color=\"green\">up 4.2%</font> after chairman Charlie Ergen<a href=\"https://www.wsj.com/articles/dishs-ergen-says-banks-lined-up-to-loan-10-billion-for-wireless-network-11576627114\" target=\"_blank\"> said</a> he has letters from three banks that are ready to offer $10B to fund DISH's new wireless network.</li><li>Ergen testified at yesterday's Sprint/T-Mobile antitrust trial and said DISH would compete with the combined entity \"from day one.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3527158\" data-linked=\"DISH +4% after revealing $10B in network financing\" data-tweet=\"$DISH - DISH +4% after revealing $10B in network financing https://seekingalpha.com/news/3527158-dishplus-4-after-revealing-10b-in-network-financing?source=tweet\" data-url=\"https://seekingalpha.com/news/3527158-dishplus-4-after-revealing-10b-in-network-financing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527157\" data-ts=\"1576685431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLT\" target=\"_blank\">FLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527157-fleetcorminus-1_1-after-citron-warns-of-ftc-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FleetCor -1.1% after Citron warns of FTC lawsuit</a></h4><ul><li>FleetCor Technologies (NYSE:<a href='https://seekingalpha.com/symbol/FLT' title='FleetCor Technologies, Inc.'>FLT</a>)<font color=\"red\"> slips 1.1%</font> after Citron Research says it expects the FTC <a href=\"https://citronresearch.com/fleetcor-citron-believes-ftc-lawsuit-is-imminent/\" target=\"_blank\">to file a lawsuit </a>against the company and force it to change its advertising/marketing and billing practices.</li><li>For years, Citron has been sour on FleetCor. In June, it<a href=\"https://seekingalpha.com/news/3469584-fleetcor-sold-100m-plus-in-phony-carbon-offsets-citron-alleges\" target=\"_blank\"> issued a report </a>calling FleetCor's Clean Advantage program a \"green fraud.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3527157\" data-linked=\"FleetCor -1.1% after Citron warns of FTC lawsuit\" data-tweet=\"$FLT - FleetCor -1.1% after Citron warns of FTC lawsuit https://seekingalpha.com/news/3527157-fleetcorminus-1_1-after-citron-warns-of-ftc-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3527157-fleetcorminus-1_1-after-citron-warns-of-ftc-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527155\" data-ts=\"1576684938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527155-cormedix-among-healthcare-gainers-akorn-and-cti-biopharma-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CorMedix among healthcare gainers; Akorn and CTI BioPharma among losers</a></h4><ul><li><b>Gainers: </b>Mirum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MIRM' title='Mirum Pharmaceuticals, Inc.'>MIRM</a>) <font color=\"green\">+40%</font>. Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals, Inc.'>SYRS</a>) <font color=\"green\">+18%</font>. Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) <font color=\"green\">+18%</font>. Galera Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GRTX' title='Galera Therapeutics, Inc.'>GRTX</a>) <font color=\"green\">+17%</font>. CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix, Inc.'>CRMD</a>) <font color=\"green\">+17%</font>.</li><li><b>Losers: </b>Emmaus Life Sciences (<a href='https://seekingalpha.com/symbol/EMMA' title='Emmaus Life Sciences, Inc.'>OTC:EMMA</a>) <font color=\"red\">-19%</font>. Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) <font color=\"red\">-17%</font>. Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences Inc.'>SLDB</a>) <font color=\"red\">-12%</font>. Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a>) <font color=\"red\">-11%</font>. CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527155\" data-linked=\"CorMedix among healthcare gainers; Akorn and CTI BioPharma among losers\" data-tweet=\"$MIRM $SYRS $APTO - CorMedix among healthcare gainers; Akorn and CTI BioPharma among losers https://seekingalpha.com/news/3527155-cormedix-among-healthcare-gainers-akorn-and-cti-biopharma-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527155-cormedix-among-healthcare-gainers-akorn-and-cti-biopharma-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527154\" data-ts=\"1576684903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527154-splunkplus-1_5-bull-sees-solid-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Splunk +1.5% as bull sees solid demand</a></h4><ul><li>Cowen sees a solid spending environment for Splunk's (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) machine analytics and SIEM markets.</li><li>Analyst Derrick Wood praises the company's new offerings over the past six months.</li><li>The analyst says he has heard of elevated sales turnover, and the new pricing structure could lead to renewal and expansion volatility.</li><li>Cowen maintains an Outperform rating and $160 price target. Splunk has a Bullish average <a href=\"https://seekingalpha.com/symbol/SPLK/ratings/sell-side-ratings?s=splk\" target=\"_blank\">Sell Side rating</a>.</li><li>Splunk shares are <font color=\"green\">up 1.5%</font> to $147.34.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527154\" data-linked=\"Splunk +1.5% as bull sees solid demand\" data-tweet=\"$SPLK - Splunk +1.5% as bull sees solid demand https://seekingalpha.com/news/3527154-splunkplus-1_5-bull-sees-solid-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3527154-splunkplus-1_5-bull-sees-solid-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527150\" data-ts=\"1576684436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527150-new-relicplus-3-cowen-sees-win-rate-improvement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Relic +3% as Cowen sees win rate improvement</a></h4><ul><li>Cowen maintains an Outperform rating and $80 target on New Relic (NYSE:<a href='https://seekingalpha.com/symbol/NEWR' title='New Relic, Inc.'>NEWR</a>) and sees improving market traction for the new Log product.</li><li>The firm sees improving win rates for NEWR against Datadog (<a href='https://seekingalpha.com/symbol/DDOG' title='Datadog, Inc.'>DDOG</a> <font color='green'>+2%</font>).</li><li>New Relic shares are <font color=\"green\">up 3.1%</font> to $68.80.</li><li>NEWR has a Bullish average <a href=\"https://seekingalpha.com/symbol/NEWR/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527150\" data-linked=\"New Relic +3% as Cowen sees win rate improvement\" data-tweet=\"$NEWR $DDOG - New Relic +3% as Cowen sees win rate improvement https://seekingalpha.com/news/3527150-new-relicplus-3-cowen-sees-win-rate-improvement?source=tweet\" data-url=\"https://seekingalpha.com/news/3527150-new-relicplus-3-cowen-sees-win-rate-improvement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527142\" data-ts=\"1576683926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWST\" target=\"_blank\">TWST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527142-twist-bio-down-4-on-bearish-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twist Bio down 4% on bearish report</a></h4><ul><li>Thinly traded Twist Bioscience (<a href='https://seekingalpha.com/symbol/TWST' title='Twist Bioscience Corporation'>TWST</a> <font color=\"red\">-4.2%</font>) slips on 50% higher volume, a modest 340K shares, in apparent response to a <a href=\"https://seekingalpha.com/article/4312885-early-2020-jury-trial-creates-high-risk-no-reward-setup-for-twist-shares\" target=\"_blank\">report</a> by The Friendly Bear who sees 50% downside ($13) from yesterday's close citing potential penalties from an intellectual property theft lawsuit brought by Agilent (<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies, Inc.'>A</a> <font color=\"red\">-0.4%</font>) who has a consistent track record of winning this type of case.</li><li>Agilent filed a whistleblower complaint with the SEC the day before Twist's IPO.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527142\" data-linked=\"Twist Bio down 4% on bearish report\" data-tweet=\"$TWST $A - Twist Bio down 4% on bearish report https://seekingalpha.com/news/3527142-twist-bio-down-4-on-bearish-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3527142-twist-bio-down-4-on-bearish-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527137\" data-ts=\"1576683279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USO\" target=\"_blank\">USO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527137-oil-price-rebounds-after-eia-reports-inventory-draw\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil price rebounds after EIA reports inventory draw</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>-1.1M</strong> barrels vs. -1.3M consensus, +0.8M last week.</li><li>Gasoline <strong>+2.5M</strong> barrels vs. +2.2M consensus, +5.4M last week.</li><li>Distillates<strong> +1.5M</strong> barrels vs. +0.3M consensus, +4.1M last week.</li><li>Oil had been modestly lower following the API last night reporting a surprise increase in inventories, but the EIA news has the price rebounding to flat on the session at $60.94.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P GSCI Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Trust II - ProShares Ultra Bloomberg Crude Oil'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='United States Brent Oil Fund, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='United States 12 Month Oil Fund, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527137\" data-linked=\"Oil price rebounds after EIA reports inventory draw\" data-tweet=\"$USO $OIL $UCO - Oil price rebounds after EIA reports inventory draw https://seekingalpha.com/news/3527137-oil-price-rebounds-after-eia-reports-inventory-draw?source=tweet\" data-url=\"https://seekingalpha.com/news/3527137-oil-price-rebounds-after-eia-reports-inventory-draw\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527134\" data-ts=\"1576683084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527134-fedex-gloom-hangs-over-transportation-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx gloom hangs over transportation sector</a></h4><ul> <li>Investors are a bit edgy about transportation and logistics stocks after FedEx (<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color=\"red\">-9.3%</font>) issued a gloomy assessment of the global economy alongside its earnings report.</li> <li>Notable decliners include XPO Logistics (<a href='https://seekingalpha.com/symbol/XPO' title='XPO Logistics, Inc.'>XPO</a> <font color=\"red\">-3.2%</font>), Forward Air (<a href='https://seekingalpha.com/symbol/FWRD' title='Forward Air Corporation'>FWRD</a> <font color=\"red\">-1.8%</font>), Hub Group (<a href='https://seekingalpha.com/symbol/HUBG' title='Hub Group, Inc.'>HUBG</a> <font color=\"red\">-1.5%</font>), Air Transport Services Group (<a href='https://seekingalpha.com/symbol/ATSG' title='Air Transport Services Group, Inc.'>ATSG</a> <font color=\"red\">-1.6%</font>), Atlas Air Worldwide Holdings (<a href='https://seekingalpha.com/symbol/AAWW' title='Atlas Air Worldwide Holdings, Inc.'>AAWW</a> <font color=\"red\">-2.4%</font>), AirT (<a href='https://seekingalpha.com/symbol/AIRT' title='Air T, Inc.'>AIRT</a>), UPS (<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a> <font color=\"red\">-1.7%</font>), Expeditors International (<a href='https://seekingalpha.com/symbol/EXPD' title='Expeditors International of Washington, Inc.'>EXPD</a> <font color=\"red\">-0.1%</font>), Echo Global Logistics (<a href='https://seekingalpha.com/symbol/ECHO' title='Echo Global Logistics, Inc.'>ECHO</a> <font color=\"red\">-2.1%</font>), USA Truck (<a href='https://seekingalpha.com/symbol/USAK' title='USA Truck, Inc.'>USAK</a> <font color=\"red\">-2.5%</font>), Saia (<a href='https://seekingalpha.com/symbol/SAIA' title='Saia, Inc.'>SAIA</a> <font color=\"red\">-1.7%</font>), Werner Enterprises (<a href='https://seekingalpha.com/symbol/WERN' title='Werner Enterprises, Inc.'>WERN</a> <font color=\"red\">-1.2%</font>), Schneider National (<a href='https://seekingalpha.com/symbol/SNDR' title='Schneider National, Inc.'>SNDR</a> <font color=\"red\">-1.1%</font>), Knight-Swift Transportation (<a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a> <font color=\"red\">-1.3%</font>) and Covenant Transportation (<a href='https://seekingalpha.com/symbol/CVTI' title='Covenant Transportation Group, Inc.'>CVTI</a> <font color=\"red\">-1.4%</font>).</li><li>The broad market is showing a slight gain on the day.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526919-fedexminus-4-after-operating-margin-plunge\" target=\"_blank\">FedEx -4% after operating margin plunge</a> (Dec. 17)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3527134\" data-linked=\"FedEx gloom hangs over transportation sector\" data-tweet=\"$FDX $XPO $FWRD - FedEx gloom hangs over transportation sector https://seekingalpha.com/news/3527134-fedex-gloom-hangs-over-transportation-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3527134-fedex-gloom-hangs-over-transportation-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527126\" data-ts=\"1576682400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYX\" target=\"_blank\">AYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527126-alteryxplus-1_7-cowen-sees-buying-opportunity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alteryx +1.7% as Cowen sees buying opportunity</a></h4><ul><li>Cowen calls last week's Alteryx (NYSE:<a href='https://seekingalpha.com/symbol/AYX' title='Alteryx, Inc.'>AYX</a>) pullback a buying opportunity.</li><li>Analyst Derrick Wood cites \"robust\" demand conditions, the \"highly favorable\" competitive environment, and guidance he thinks is conservative.</li><li>Wood maintains an Outperform rating and $147 target on AYX. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/AYX/ratings/sell-side-ratings?s=ayx\" target=\"_blank\">Sell Side rating</a>.</li><li>Alteryx shares are <font color=\"green\">up 1.7%</font> to $99.06. AYX is <font color=\"red\">down 9.5%</font> in the past week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527126\" data-linked=\"Alteryx +1.7% as Cowen sees buying opportunity\" data-tweet=\"$AYX - Alteryx +1.7% as Cowen sees buying opportunity https://seekingalpha.com/news/3527126-alteryxplus-1_7-cowen-sees-buying-opportunity?source=tweet\" data-url=\"https://seekingalpha.com/news/3527126-alteryxplus-1_7-cowen-sees-buying-opportunity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527118\" data-ts=\"1576681471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CI\" target=\"_blank\">CI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527118-cignaplus-2_6-on-6_3b-deal-stock-buyback-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cigna +2.6% on $6.3B deal, stock buyback boost</a></h4><ul><li>Cigna (NYSE:<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a>)<font color=\"green\"> gains 2.6% </font>after announcing it<a href=\"https://seekingalpha.com/pr/17731444-new-york-life-to-acquire-cigna-s-group-life-and-disability-insurance-business\" target=\"_blank\"> will sell </a>its group life and disability insurance business to New York Life for $6.3B in a move to focus on its core growth platform.</li><li>Expects to use ~$5.3B of net after-tax proceeds from the deal for share repurchases and repayment of debt in 2020.</li><li>Cigna's board also boosts the company's share repurchase authorization to $4.0B from $3.0B.</li><li>Sees deal neutral to 2020 EPS and adding modestly to 2021 EPS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527118\" data-linked=\"Cigna +2.6% on $6.3B deal, stock buyback boost\" data-tweet=\"$CI - Cigna +2.6% on $6.3B deal, stock buyback boost https://seekingalpha.com/news/3527118-cignaplus-2_6-on-6_3b-deal-stock-buyback-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3527118-cignaplus-2_6-on-6_3b-deal-stock-buyback-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527117\" data-ts=\"1576681464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNPS\" target=\"_blank\">SNPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527117-synopsysplus-1_4-on-berenberg-target-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synopsys +1.4% on Berenberg target boost</a></h4><ul><li>Berenberg raises its Synopsys (NASDAQ:<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a>) target from $152 to $158, citing the \"solid\" Q4 results earlier this month.</li><li>Analyst Joshua Tilton sees \"strong demand\" for the electronic design automation and software integrity products, which will offset \"lumpy\" revenue streams from seasonality.</li><li>Berenberg maintains a Buy rating on SNPS. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/SNPS/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Synopsys shares are <font color=\"green\">up 1.4%</font> to $138.88.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527117\" data-linked=\"Synopsys +1.4% on Berenberg target boost\" data-tweet=\"$SNPS - Synopsys +1.4% on Berenberg target boost https://seekingalpha.com/news/3527117-synopsysplus-1_4-on-berenberg-target-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3527117-synopsysplus-1_4-on-berenberg-target-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527111\" data-ts=\"1576680929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCAP\" target=\"_blank\">JCAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527111-jernigan-capital-continues-higher-after-internalization-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jernigan Capital continues higher after internalization plan</a></h4><ul><li>Jernigan Capital (NYSE:<a href='https://seekingalpha.com/symbol/JCAP' title='Jernigan Capital, Inc.'>JCAP</a>) on Monday night <a href=\"https://seekingalpha.com/pr/17729573-jernigan-capital-inc-announces-agreement-to-internalize-external-manager\" target=\"_blank\">announced an all-stock agreement </a>to internalize management, with closing seen in Q1 of 2020.</li><li>Net G&amp;A savings of about $17.8M are expected, and the deal is seen as immediately accretive to EPS, adjusted EPS, and free cash flow per share.</li><li>The dividend is to be \"right-sized,\" with the new annual rate being $0.92 per share vs. the previous $1.40.</li><li>Shares are up another 0.8% today, trading at $18.91 vs. about $17.50 prior to the announcement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527111\" data-linked=\"Jernigan Capital continues higher after internalization plan\" data-tweet=\"$JCAP - Jernigan Capital continues higher after internalization plan https://seekingalpha.com/news/3527111-jernigan-capital-continues-higher-after-internalization-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3527111-jernigan-capital-continues-higher-after-internalization-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527109\" data-ts=\"1576680747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/M\" target=\"_blank\">M</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527109-macys-gains-on-cleveland-research-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macy&#39;s gains on Cleveland Research confidence</a></h4><ul> <li>Macy's (<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s, Inc.'>M</a> <font color='green'>+2.9%</font>) is higher after Cleveland Research says the department store chain dialed back promotional activity in Q4 and is seeing a sequential improvement in comparable store sales growth.</li> <li>Notes from Cleveland Research tend to carry a lot of weight in the retail sector.</li> <li>Shares of Macy's are still down 45% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527109\" data-linked=\"Macy&#39;s gains on Cleveland Research confidence\" data-tweet=\"$M - Macy&#39;s gains on Cleveland Research confidence https://seekingalpha.com/news/3527109-macys-gains-on-cleveland-research-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3527109-macys-gains-on-cleveland-research-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527097\" data-ts=\"1576679564\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527097-seaworld-gains-on-b-riley-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaWorld gains on B. Riley confidence</a></h4><ul> <li>B. Riley lifts its price target on SeaWorld Entertainment (<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment, Inc.'>SEAS</a> <font color='green'>+1.3%</font>) to a Street-high $42 after meeting with the theme park company's management team. The new price target from B. Riley is well-above the <a href=\"https://seekingalpha.com/symbol/SEAS/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $33.91.</li> <li>Analyst Eric Wold and team say they came away from a tour of new attractions at SeaWorld Orlando \"increasingly confident\" in the ability of SeaWorld to top its own 2020 guidance.</li> <li>\"Even though SEAS shares have essentially tripled since their all-time lows in late 2017, we would argue that the expanded attendance reach provided by the accelerated efforts to add more rides and attractions to the parks along with the attractive operating leverage on future attendance gains provided by the successful expense management efforts provides a positive set-up for meaningful valuation multiple expansion in the coming years,\" writes Wold.</li> <li>Looking even further ahead, Wold notes that SeaWorld is more likely to monetize undeveloped land and out-of-park developments with Sergio Rivera as the new CEO.</li> <li>B. Riley's price target factors in a 9.5X multiple off the 2020 AEBITDA estimate.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527097\" data-linked=\"SeaWorld gains on B. Riley confidence\" data-tweet=\"$SEAS - SeaWorld gains on B. Riley confidence https://seekingalpha.com/news/3527097-seaworld-gains-on-b-riley-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3527097-seaworld-gains-on-b-riley-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527090\" data-ts=\"1576678919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSG\" target=\"_blank\">TSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527090-stars-group-lower-after-block-trade-priced\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stars Group lower after block trade priced</a></h4><ul> <li>The Stars Group (NASDAQ:<a href='https://seekingalpha.com/symbol/TSG' title='The Stars Group Inc.'>TSG</a>) is <font color=\"red\">down 2.55%</font> premarket after a 15M-share block trade was priced at $23.74 per share.</li> <li>CVC Partners reportedly unloaded the block of shares.</li><li>Average daily volume on Stars Group is about 3.4M shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3527090\" data-linked=\"Stars Group lower after block trade priced\" data-tweet=\"$TSG - Stars Group lower after block trade priced https://seekingalpha.com/news/3527090-stars-group-lower-after-block-trade-priced?source=tweet\" data-url=\"https://seekingalpha.com/news/3527090-stars-group-lower-after-block-trade-priced\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527089\" data-ts=\"1576678909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYRS\" target=\"_blank\">SYRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527089-syros-and-global-blood-go-opposite-ways-on-collaboration-announcement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syros and Global Blood go opposite ways on collaboration announcement</a></h4><ul><li>Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals, Inc.'>SYRS</a>) (<font color=\"green\">+6%</font> premarket) and Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics, Inc.'>GBT</a>) (<font color=\"red\">-6%</font> premarket) will <a href=\"https://seekingalpha.com/pr/17731326-gbt-and-syros-partner-to-discover-develop-and-commercialize-novel-therapies-for-sickle-cell\" target=\"_blank\">collaborate </a>to discover, develop and commercialize new treatments for sickle cell disease and beta thalassemia.</li><li>Syros will leverage its gene control platform to identify therapeutic targets and GBT will have an option to in-license exclusive global rights to the candidates.</li><li>Under the terms of the deal, GBT will pay Syros $20M upfront, up to $40M in preclinical research funding, up to $315M in milestones and other payments per candidate and mid-to-high single-digit royalties on net sales. Syros will have the option to co-promote the first product in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527089\" data-linked=\"Syros and Global Blood go opposite ways on collaboration announcement\" data-tweet=\"$SYRS $GBT - Syros and Global Blood go opposite ways on collaboration announcement https://seekingalpha.com/news/3527089-syros-and-global-blood-go-opposite-ways-on-collaboration-announcement?source=tweet\" data-url=\"https://seekingalpha.com/news/3527089-syros-and-global-blood-go-opposite-ways-on-collaboration-announcement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527087\" data-ts=\"1576678720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527087-ssl-lmpx-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SSL, LMPX among premarket gainers</a></h4><ul><li>YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"green\">+39%</font> on entering into a new <a href=\"https://seekingalpha.com/pr/17731556-yayyo-inc-enters-rideshare-rental-fleet-partnership-lmp-automotive-holdings\" target=\"_blank\">fleet partnership</a> with LMP Automotive Holdings.</li><li>Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences Inc.'>SLDB</a>) <font color=\"green\">+19%</font> on providing <a href=\"https://seekingalpha.com/news/3527012-solid-biosciences-down-1-premarket-on-dmd-gene-therapy-update\" target=\"_blank\">update</a> on DMD gene therapy.</li><li>ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals Limited'>ASLN</a>) <font color=\"green\">+12%</font>.</li><li>Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals, Inc.'>SYRS</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/pr/17731326-gbt-and-syros-partner-to-discover-develop-and-commercialize-novel-therapies-for-sickle-cell\" target=\"_blank\">collaborating</a> with Global Blood Therapeutics for sickle cell disease and beta thalassemia.</li><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"green\">+10%</font> after submitting a <a href=\"https://seekingalpha.com/news/3526976-pg-and-e-reaches-1_6b-wildfire-settlement\" target=\"_blank\">multiparty settlement agreement</a> related to the 2017 and 2018 wildfires.</li><li>Sasol (NYSE:<a href='https://seekingalpha.com/symbol/SSL' title='Sasol Limited'>SSL</a>) <font color=\"green\">+9%</font>.</li><li>LMP Automotive Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+9%</font> on entering into a new <a href=\"https://seekingalpha.com/pr/17731556-yayyo-inc-enters-rideshare-rental-fleet-partnership-lmp-automotive-holdings\" target=\"_blank\">fleet partnership</a> with YayYo.</li><li>Boxlight (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight Corporation'>BOXL</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/pr/17731598-boxlight-to-outfit-entire-south-carolina-school-district-interactive-multi-touch-panels\" target=\"_blank\">outfitting</a> South Carolina school district with interactive multi-touch panels.</li><li>Verb Technology Company (NASDAQ:<a href='https://seekingalpha.com/symbol/VERB' title='Verb Technology Company, Inc.'>VERB</a>) <font color=\"green\">+5%</font> on <a href=\"https://seekingalpha.com/pr/17731185-verb-to-appoint-former-apple-executive-nancy-heinen-to-board-of-directors\" target=\"_blank\">appointing</a> Nancy Heinen to Board of Directors.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527087\" data-linked=\"SSL, LMPX among premarket gainers\" data-tweet=\"$YAYO $SLDB $ASLN - SSL, LMPX among premarket gainers https://seekingalpha.com/news/3527087-ssl-lmpx-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527087-ssl-lmpx-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527081\" data-ts=\"1576677960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527081-fdx-aey-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDX, AEY among premarket losers</a></h4><ul><li>Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a>) <font color=\"red\">-10%</font> after Novartis bails on Aduro's <a href=\"https://seekingalpha.com/news/3526951-novartis-bails-on-aduros-adu-s100\" target=\"_blank\">ADU-S100</a>.</li><li>ADDvantage Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AEY' title='ADDvantage Technologies Group, Inc.'>AEY</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3526916-addvantage-technologies-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li><li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3526912-fedex-eps-misses-0_27-misses-on-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics, Inc.'>GBT</a>) <font color=\"red\">-7%</font> after entering into a $150M <a href=\"https://seekingalpha.com/pr/17731346-gbt-secures-150-million-non-dilutive-term-loan-financing\" target=\"_blank\">loan agreement</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527081\" data-linked=\"FDX, AEY among premarket losers\" data-tweet=\"$ADRO $AEY $FDX - FDX, AEY among premarket losers https://seekingalpha.com/news/3527081-fdx-aey-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527081-fdx-aey-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527080\" data-ts=\"1576677954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLO\" target=\"_blank\">ALLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527080-morgan-stanley-sees-20-upside-in-lilly-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley sees 20% upside in Lilly in premarket analyst action</a></h4><ul><li>Allogene Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLO' title='Allogene Therapeutics, Inc.'>ALLO</a>) initiated with Market Perform rating and $37 (36% upside) price target at JMP Securities.</li><li>CorMedix (NYSEMKT:<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix, Inc.'>CRMD</a>) initiated with Buy rating and $15 (129% upside) price target at B. Riley FBR. Shares up <font color=\"green\">4%</font> premarket.</li><li>Fortress Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>) resumed with Buy rating and $9 (348% upside) price target at B. Riley FBR. Shares up <font color=\"green\">4% </font>premarket.</li><li>Iovance Biotherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a>) initiated with Market Perform rating at JMP Securities. Shares up <font color=\"green\">2%</font> premarket.</li><li>OPKO Health (NASDAQ:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) initiated with Neutral rating at Guggenheim.</li><li>Optinose (NASDAQ:<a href='https://seekingalpha.com/symbol/OPTN' title='OptiNose, Inc.'>OPTN</a>) initiated with Outperform rating and $25 (181% upside) price target at Cowen and Company.</li><li>SI-BONE (NASDAQ:<a href='https://seekingalpha.com/symbol/SIBN' title='SI-BONE, Inc.'>SIBN</a>) initiated with Overweight rating and $27 (36% upside) price target at Cantor Fitzgerald.</li><li>SmileDirectClub (NASDAQ:<a href='https://seekingalpha.com/symbol/SDC' title='SmileDirectClub, Inc.'>SDC</a>) initiated with Neutral rating and $10 (28% upside) price target at Goldman Sachs. Shares up <font color=\"green\">1% </font>premarket.</li><li>X4 Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/XFOR' title='X4 Pharmaceuticals, Inc.'>XFOR</a>) initiated with Buy rating and $20 (82% upside) price target at Roth Capital.</li><li>Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) upgraded to Buy with a $4 (182% upside) price target at Maxim Group.</li><li>Healthcare Trust of America (NYSE:<a href='https://seekingalpha.com/symbol/HTA' title='Healthcare Trust of America, Inc.'>HTA</a>) upgraded to Overweight with a $32 (10% upside) price target at JPMorgan.</li><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) upgraded to Overweight with a $150 (20% upside) price target at Morgan Stanley. Shares up <font color=\"green\">1% </font>premarket.</li><li>Sabra Health Care REIT (NASDAQ:<a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a>) upgraded to Neutral at Citigroup. Shares up <font color=\"green\">7%</font> premarket.</li><li>Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro BioTech, Inc.'>ADRO</a>) downgraded to Market Perform at William Blair. Shares down <font color=\"red\">15%</font> premarket after Novartis <a href=\"https://seekingalpha.com/news/3526951-novartis-bails-on-aduros-adu-s100\" target=\"_blank\">exit</a> from ADU-S100.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527080\" data-linked=\"Morgan Stanley sees 20% upside in Lilly in premarket analyst action\" data-tweet=\"$ALLO $CRMD $FBIO - Morgan Stanley sees 20% upside in Lilly in premarket analyst action https://seekingalpha.com/news/3527080-morgan-stanley-sees-20-upside-in-lilly-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3527080-morgan-stanley-sees-20-upside-in-lilly-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527066\" data-ts=\"1576677341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCRD\" target=\"_blank\">TCRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527066-thl-credit-authorizes-share-repurchase-program-sharesplus-12-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">THL Credit authorizes share repurchase program; shares +12% PM</a></h4><ul><li>THL Credit (NASDAQ:<a href='https://seekingalpha.com/symbol/TCRD' title='THL Credit'>TCRD</a>) authorizes a new share repurchase program for up to $10M of its outstanding common stock, effective Dec. 17, 2019.</li><li>The share repurchase may be made in the open market or through privately negotiated transactions, including block purchases or by way of an accelerated share repurchase program, from time-to-time through Dec. 16, 2020.</li><li><a href=\"https://seekingalpha.com/filing/4738947\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527066\" data-linked=\"THL Credit authorizes share repurchase program; shares +12% PM\" data-tweet=\"$TCRD - THL Credit authorizes share repurchase program; shares +12% PM https://seekingalpha.com/news/3527066-thl-credit-authorizes-share-repurchase-program-sharesplus-12-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3527066-thl-credit-authorizes-share-repurchase-program-sharesplus-12-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527063\" data-ts=\"1576676855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAYX\" target=\"_blank\">PAYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527063-paychexplus-2-after-beat-and-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paychex +2% after beat-and-raise</a></h4><ul><li>Paychex (NASDAQ:<a href='https://seekingalpha.com/symbol/PAYX' title='Paychex, Inc.'>PAYX</a>) <font color=\"green\">+2%</font> <a href=\"https://seekingalpha.com/news/3527055-paychex-eps-beats-0_02-beats-on-revenue\" target=\"_blank\">reports Q2 beats</a> and raises the FY20 EPS outlook from $3.10 to about $3.10-3.12. Management Solutions revenue growth is expected between 5% and 5.5%.</li><li>In Q2, Management Solutions contributed $726.7M in revenue and PEO and Insurance Services totaled $244.1M.</li><li>Adjusted EBITDA was $398.8M versus the $386.4M consensus.</li><li>Funds held for clients totaled $19.9M.</li><li>Earnings call starts at 9:30 AM with a webcast <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.paychex.com%2Finvestors&amp;esheet=52148435&amp;newsitemid=20191218005062&amp;lan=en-US&amp;anchor=Investor+Relations+Page&amp;index=4&amp;md5=0265b16caace40d59803f9b32e204b8d\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17731528-paychex-inc-reports-second-quarter-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527063\" data-linked=\"Paychex +2% after beat-and-raise\" data-tweet=\"$PAYX - Paychex +2% after beat-and-raise https://seekingalpha.com/news/3527063-paychexplus-2-after-beat-and-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3527063-paychexplus-2-after-beat-and-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527059\" data-ts=\"1576676470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527059-fedexminus-8-analyst-gloom-rains-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx -8% as analyst gloom rains down</a></h4><ul> <li>Oppenheimer lowers FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) to a Perform rating after having it slotted at Outperform.</li> <li>\"With Express/Ground margins well below historical trend, we anticipate FedEx to be a 'show me' story for multiple quarters,\" warns analyst Scott Schneeberger.</li> <li>The firm lowers its 2020-2021 EPS estimates on FedEx in reaction to the shipper's weak macroeconomic outlook.</li> <li>Cowen also came in this morning with a price target cut on FDX to $185 from $190.</li> <li>Deutsche Bank calls the numbers turned in FedEx \"breathtakingly bad\" in its post-earnings assessment.</li><li>There's likely to be a few more shots on FDX from Wall Street analysts before the day is over.</li> <li>Shares of FedEx are <font color=\"red\">down 7.75%</font> premarket to $150.58.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526912-fedex-eps-misses-0_27-misses-on-revenue\" target=\"_blank\">FedEx EPS misses by $0.27, misses on revenue</a> (Dec. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526919-fedexminus-4-after-operating-margin-plunge\" target=\"_blank\">FedEx -4% after operating margin plunge</a> (Dec. 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527059\" data-linked=\"FedEx -8% as analyst gloom rains down\" data-tweet=\"$FDX - FedEx -8% as analyst gloom rains down https://seekingalpha.com/news/3527059-fedexminus-8-analyst-gloom-rains-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3527059-fedexminus-8-analyst-gloom-rains-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527058\" data-ts=\"1576676464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGN\" target=\"_blank\">NTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527058-neon-to-start-cell-therapy-trial-in-europe-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neon to start cell therapy trial in Europe; shares up 3% premarket</a></h4><ul><li>Neon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics, Inc.'>NTGN</a>) has <a href=\"https://seekingalpha.com/pr/17731466-neon-therapeutics-submits-european-clinical-trial-authorization-application-for-personal\" target=\"_blank\">filed</a> a Clinical Trial Authorization &#40;CTA&#41; with the Dutch Health Authority for the evaluation of NEO-PTC-01 in patients with metastatic melanoma who are refractory to checkpoint inhibitors.</li><li>NEO-PTC-01 is a personal neoantigen-targeted T cell therapy candidate derived from patients\u2019 peripheral blood mononuclear cells.</li>   <li>The company plans to initiate a Phase 1 dose escalation trial in metastatic melanoma in collaboration with the Netherlands Cancer Institute in H1 2020.</li><li>Shares are up <font color=\"green\">3%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3527058\" data-linked=\"Neon to start cell therapy trial in Europe; shares up 3% premarket\" data-tweet=\"$NTGN - Neon to start cell therapy trial in Europe; shares up 3% premarket https://seekingalpha.com/news/3527058-neon-to-start-cell-therapy-trial-in-europe-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3527058-neon-to-start-cell-therapy-trial-in-europe-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527054\" data-ts=\"1576675935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTON\" target=\"_blank\">PTON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527054-bernstein-talks-up-peloton\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bernstein talks up Peloton</a></h4><ul> <li>Peloton Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) tracks slightly higher in early trading after Bernstein hikes its price target to $39 from $29.</li> <li>Bernstein takes a favorable view of Peloton's margin profile and observes that the lifetime value of a PTON subscriber is high despite the customer acquisition costs.</li> <li>Bernstein sticks with an Outperform rating. On Wall Street, <a href=\"https://seekingalpha.com/symbol/PTON/ratings/sell-side-ratings\" target=\"_blank\">20</a> out of 21 firms covering Peloton have a Buy-equivalent rating, while on Seeking Alpha only 4 of 12 authors with an article out are in the bull camp.</li> <li>Shares of Peloton are <font color=\"green\">up 0.21%</font> premarket to $33.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527054\" data-linked=\"Bernstein talks up Peloton\" data-tweet=\"$PTON - Bernstein talks up Peloton https://seekingalpha.com/news/3527054-bernstein-talks-up-peloton?source=tweet\" data-url=\"https://seekingalpha.com/news/3527054-bernstein-talks-up-peloton\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527049\" data-ts=\"1576675467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAL\" target=\"_blank\">HAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527049-halliburton-down-1_3-bmo-bails-on-buy-recommendation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halliburton down 1.3% as BMO bails on buy recommendation</a></h4><ul><li>Overall, it's been a rough year for the stock, but shares have bounced in a big way since August (<font color=\"green\">up more than 40%</font>). Further outperformance would require positive estimate revisions, says analyst Daniel Boyd, downgrading to Market Perform from Outperform.</li><li><a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color=\"red\">-1.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3527049\" data-linked=\"Halliburton down 1.3% as BMO bails on buy recommendation\" data-tweet=\"$HAL - Halliburton down 1.3% as BMO bails on buy recommendation https://seekingalpha.com/news/3527049-halliburton-down-1_3-bmo-bails-on-buy-recommendation?source=tweet\" data-url=\"https://seekingalpha.com/news/3527049-halliburton-down-1_3-bmo-bails-on-buy-recommendation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527043\" data-ts=\"1576675000\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527043-dar-bioplus-11-premarket-on-receiving-fda-clearance-for-dare-bv1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daré Bio +11% premarket on receiving FDA clearance for DARE-BV1</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17731411-dar-bioscience-announces-fda-clearance-of-ind-application-for-dare-bv1-for-bacterial\" target=\"_blank\">cleared</a> Daré Bioscience's (NASDAQ:<a href='https://seekingalpha.com/symbol/DARE' title='Daré Bioscience, Inc.'>DARE</a>) investigational new drug &#40;IND&#41; application for DARE-BV1, its thermosetting bioadhesive hydrogel containing 2% clindamycin phosphate being developed for one-time vaginal administration for the treatment of bacterial vaginosis.</li>   <li>With this clearance, Daré can commence the Phase 3 study of DARE-BV1 in ~220 women in 2020 to support the NDA submission.</li><li>Shares are up <font color=\"green\">11%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3527043\" data-linked=\"Daré Bio +11% premarket on receiving FDA clearance for DARE-BV1\" data-tweet=\"$DARE - Daré Bio +11% premarket on receiving FDA clearance for DARE-BV1 https://seekingalpha.com/news/3527043-dar-bioplus-11-premarket-on-receiving-fda-clearance-for-dare-bv1?source=tweet\" data-url=\"https://seekingalpha.com/news/3527043-dar-bioplus-11-premarket-on-receiving-fda-clearance-for-dare-bv1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527041\" data-ts=\"1576674521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527041-vivus-down-1-premarket-on-qsymia-data-in-obese-adolescents\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivus down 1% premarket on Qsymia data in obese adolescents</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17731361-vivus-announces-new-data-supporting-safety-and-efficacy-of-qsymia-in-adolescents-obesity\" target=\"_blank\">Results </a>from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02714062?term=NCT02714062&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 4 study</a> evaluating VIVUS' (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) Qsymia (phentermine and topiramate extended-release) capsules CIV in 42 obese adolescents showed favorable pharmacokinetic, efficacy, and safety/tolerability profiles when used for eight weeks. The aim of the trial was to establish dosing levels for an ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT03922945?lead=vivus&amp;phase=3&amp;draw=2&amp;rank=1\" target=\"_blank\">post-marketing study</a> in this patient population.</li><li>Weight loss ranged from -3.72 - 4.96% at day 56 compared to a +1.06% gain in the control arm.</li><li>No new safety signals were observed.</li><li>Shares down <font color=\"red\">1%</font> premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527041\" data-linked=\"Vivus down 1% premarket on Qsymia data in obese adolescents\" data-tweet=\"$VVUS - Vivus down 1% premarket on Qsymia data in obese adolescents https://seekingalpha.com/news/3527041-vivus-down-1-premarket-on-qsymia-data-in-obese-adolescents?source=tweet\" data-url=\"https://seekingalpha.com/news/3527041-vivus-down-1-premarket-on-qsymia-data-in-obese-adolescents\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527039\" data-ts=\"1576674410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527039-realrealplus-1-on-b-riley-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RealReal +1% on B. Riley confidence</a></h4><ul> <li>RealReal (NASDAQ:<a href='https://seekingalpha.com/symbol/REAL' title='The RealReal, Inc.'>REAL</a>) is on watch after B. Riley initiates <a href=\"https://www.cnbc.com/2019/12/18/stocks-making-the-biggest-moves-premarket-fedex-general-mills-pge-cigna-more.html\" target=\"_blank\">coverage</a> on the online retailer with a Buy rating.</li> <li>The research firm led by analyst Susan Anderson sees RealReal positioned well in the luxury goods retail market. \"We view REAL as the leader in the modern-day luxury consignment market whose model is disrupting traditional consignment shops by providing an essentially seamless and hassle-free experience for consumers from consignment to purchase. We expect the growth of the luxury goods market, coupled with consumers' increasing willingness to purchase secondhand products, to drive growth for REAL. Additionally, we believe that REAL's seamless model will encourage more consumers to move into luxury consignment (either as purchasers or consigners) and that REAL increases access to luxury goods for consumers who otherwise would not be able to afford them,\" reads the firm's note.</li> <li>B. Riley assigns a price target of $23 to RealReal.</li> <li>Shares of RealReal are <font color=\"green\">up 0.92%</font> in premarket trading to $17.59.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527039\" data-linked=\"RealReal +1% on B. Riley confidence\" data-tweet=\"$REAL - RealReal +1% on B. Riley confidence https://seekingalpha.com/news/3527039-realrealplus-1-on-b-riley-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3527039-realrealplus-1-on-b-riley-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527034\" data-ts=\"1576673957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIS\" target=\"_blank\">GIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527034-general-millsplus-2-on-pet-segment-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Mills +2% on pet segment strength</a></h4><ul> <li>General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>) rallies after organic sales rose 1% in <a href=\"https://seekingalpha.com/pr/17731295-general-mills-reports-fiscal-2020-second-quarter-results-and-reaffirms-full-year-guidance\" target=\"_blank\">FQ2</a>. Organic volume was up 1% during the period and organic net price realization and mix was in line with last year. The pet segment saw a 16% jump in organic sales vs. +15.0% anticipated.</li> <li>Gross margin rose 80 bps Y/Y to 35.3% of sales vs. 34.7% consensus. Operating profit margin increased 110 basis points to 18.4% of sales vs. 17.3% consensus.</li> <li>Looking ahead, General Mills sees organic sales growth of +1% to +2% and EPS growth +3% to +5% vs. +4% consensus.</li><li>Shares of General Mills are <font color=\"green\">up 2.51%</font> premarket to $53.48.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527006-general-mills-eps-beats-0_07-misses-on-revenue\" target=\"_blank\">General Mills EPS beats by $0.07, misses on revenue</a> (Dec. 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527034\" data-linked=\"General Mills +2% on pet segment strength\" data-tweet=\"$GIS - General Mills +2% on pet segment strength https://seekingalpha.com/news/3527034-general-millsplus-2-on-pet-segment-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3527034-general-millsplus-2-on-pet-segment-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527021\" data-ts=\"1576672556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKX\" target=\"_blank\">SKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527021-deutsche-bank-joins-bull-camp-on-skechers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank joins bull camp on Skechers</a></h4><ul> <li>Deutsche Bank starts off coverage on Skechers (NYSE:<a href='https://seekingalpha.com/symbol/SKX' title='Skechers U.S.A., Inc.'>SKX</a>) with a Buy rating.</li> <li>The research firm assigns a price target of $49 on SKX vs. the <a href=\"https://seekingalpha.com/symbol/SKX/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $45.00. On Wall Street, nine out of thirteen firms covering Skechers have a Buy-equivalent rating on the books.</li> <li>Shares of Skechers are <font color=\"green\">up 0.27%</font> premarket to $41.51. vs. the 52-week trading range of $21.45 to $42.22.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527021\" data-linked=\"Deutsche Bank joins bull camp on Skechers\" data-tweet=\"$SKX - Deutsche Bank joins bull camp on Skechers https://seekingalpha.com/news/3527021-deutsche-bank-joins-bull-camp-on-skechers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527021-deutsche-bank-joins-bull-camp-on-skechers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527017\" data-ts=\"1576672173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDOG\" target=\"_blank\">DDOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527017-datadogplus-1_4-on-new-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Datadog +1.4% on new Street-high target</a></h4><ul><li>Rosenblatt starts Datadog (NASDAQ:<a href='https://seekingalpha.com/symbol/DDOG' title='Datadog, Inc.'>DDOG</a>) with a Buy rating and $50 target. DDOG has a Bullish average <a href=\"https://seekingalpha.com/symbol/DDOG/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Analyst Yun Kim calls DDOG \"well-positioned\" to benefit from cloud-monitoring market growth.</li><li>Datadog \"has already garnered a significant mind share lead\" and should continue gaining traction, says Kim.</li><li>DDOG shares are<font color=\"green\"> up 1.4%</font> pre-market to $37.71.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527017\" data-linked=\"Datadog +1.4% on new Street-high target\" data-tweet=\"$DDOG - Datadog +1.4% on new Street-high target https://seekingalpha.com/news/3527017-datadogplus-1_4-on-new-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3527017-datadogplus-1_4-on-new-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527013\" data-ts=\"1576671319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527013-epizyme-shares-halted-for-todays-ad-com-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme shares halted for today&#39;s Ad Com review</a></h4><ul><li>Nasdaq has suspended trading in Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme, Inc.'>EPZM</a>) pending the release of news, in this case, the outcome of today's <a href=\"https://seekingalpha.com/news/3526571-fda-ad-com-this-week-for-epizymes-tazemetostat-for-epitheloid-sarcoma\" target=\"_blank\">FDA advisory committee meeting</a> on its application for tazemetostat for epithelioid sarcoma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527013\" data-linked=\"Epizyme shares halted for today&#39;s Ad Com review\" data-tweet=\"$EPZM - Epizyme shares halted for today&#39;s Ad Com review https://seekingalpha.com/news/3527013-epizyme-shares-halted-for-todays-ad-com-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3527013-epizyme-shares-halted-for-todays-ad-com-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527012\" data-ts=\"1576671102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLDB\" target=\"_blank\">SLDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527012-solid-biosciences-down-1-premarket-on-dmd-gene-therapy-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Solid Biosciences down 1% premarket on DMD gene therapy update</a></h4><ul><li>Solid Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences Inc.'>SLDB</a>) slips <font color=\"red\">1%</font> premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17731260-solid-biosciences-provides-data-update-from-sgtminus-001-development-program\" target=\"_blank\">update </a>on its Phase 1/2 clinical trial evaluating Duchenne muscular dystrophy &#40;DMD&#41; gene transfer candidate SGT-001.</li><li>The serious adverse event in the third patient treated in the 2E14 vg/kg dose arm has fully resolved and he has resumed normal activities, although the FDA's <a href=\"https://seekingalpha.com/news/3517892-solid-bio-down-59-premarket-on-another-clinical-hold-on-dmd-gene-therapy\" target=\"_blank\">clinical hold</a> is still in effect (the second such action on the study).</li><li>The company says biomarket data on two subjects show \"evidence\" that SGT-001 \"has the potential\" to deliver therapeutic benefit.</li><li>Six patients have been dosed thus far. Three-month muscle biopsies from subjects #4 and #5 in the 2E14 vg/kg arm showed that 10-20% of microdystrophin-positive muscle fibers expressed SGT-001 microdystrophin in #4 and 50-70% in #5.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the data.</li><li><strong>Update</strong>: Shares now up <font color=\"green\">18%</font> premarket on robust volume in apparent reaction to the resolution of the adverse event.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527012\" data-linked=\"Solid Biosciences down 1% premarket on DMD gene therapy update\" data-tweet=\"$SLDB - Solid Biosciences down 1% premarket on DMD gene therapy update https://seekingalpha.com/news/3527012-solid-biosciences-down-1-premarket-on-dmd-gene-therapy-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3527012-solid-biosciences-down-1-premarket-on-dmd-gene-therapy-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527001\" data-ts=\"1576670211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527001-amc-entertainmentminus-4-after-baml-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Entertainment -4% after BAML cut</a></h4><ul> <li>Bank of America Merrill Lynch drops AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc.'>AMC</a>) to an Underperform rating from Neutral on concerns over the 2020 slate of films.</li> <li>The firm also warns on a reduction of AMC's dividend in the back half of the year.</li> <li>BAML lowers its price target on AMC to $7 from $14 vs. the <a href=\"https://seekingalpha.com/symbol/AMC/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $14.17.</li> <li>Shares of AMC are <font color=\"red\">down 3.82%</font> premarket to $7.81.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527001\" data-linked=\"AMC Entertainment -4% after BAML cut\" data-tweet=\"$AMC - AMC Entertainment -4% after BAML cut https://seekingalpha.com/news/3527001-amc-entertainmentminus-4-after-baml-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3527001-amc-entertainmentminus-4-after-baml-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}